Sugi Predict

Sugi Predict / Compounds / SCHEMBL3877263

SCHEMBL3877263

SCHEMBL3877263

COc1ccc(-c2ccc(C(=O)NCCc3ccc(C(C)N4CCCC4)cc3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.56
▸ POLB P06746 1/20 0.53
▸ RAB9A P51151 6/20 0.53
▸ MAPT P10636 4/20 0.53
▸ LMNA P02545 3/20 0.53
▸ MCHR1 Q99705 4/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CHRM1 P11229 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ TP53 P04637 1/20 0.50
▸ NAMPT P43490 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3871649 0.99 KDM4E (0.55) KDM4EPOLBRAB9AMAPTLMNA
SCHEMBL3868681 0.99 KDM4E (0.55) KDM4EPOLBRAB9AMAPTLMNA
SCHEMBL3879855 0.92 KDM4E (0.54) KDM4EPOLBRAB9AMAPTLMNA
SCHEMBL3872340 0.88 ALDH1A1 (0.58) KDM4ERAB9AMAPTLMNAMCHR1
SCHEMBL3868712 0.88 MCHR1 (0.55) KDM4ERAB9AMAPTLMNAMCHR1
SCHEMBL3873986 0.88 TRPV1 (0.53) MCHR1CYP2D6CHRM1HTR2ASMN1; SMN2
SCHEMBL3870885 0.87 ALDH1A1 (0.57) KDM4ERAB9AMAPTLMNAMCHR1
SCHEMBL3870079 0.87 ALDH1A1 (0.57) KDM4ERAB9AMAPTLMNAMCHR1
SCHEMBL3881228 0.87 MCHR1 (0.67) KDM4ERAB9AMAPTLMNAMCHR1
SCHEMBL3879241 0.87 MCHR1 (0.69) RAB9AMAPTMCHR1CYP2D6CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-7601868-B2 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-13 — — US disclosed
US-20060128690-A1 Amine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-15 — — US disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128690-A1 Amine derivative MC1R, MC2R, MC4R KDM4E 1415/4885POLB 4062/4885RAB9A 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.